Geburtshilfe Frauenheilkd 2013; 73(9): 874-889
DOI: 10.1055/s-0033-1350713
GebFra Science
Georg Thieme Verlag KG Stuttgart · New York

S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours

Short version 1.0 – AWMF registration number: 032/035OL, June 2013S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner OvarialtumorenKurzversion 1.0 – AWMF-Registernummer: 032/035OL, Juni 2013
U. Wagner
P. Harter
F. Hilpert
S. Mahner
A. Reuß
A. du Bois
E. Petru
W. Meier
P. Ortner
K. König
K. Lindel
D. Grab
P. Piso
O. Ortmann
I. Runnebaum
J. Pfisterer
D. Lüftner
N. Frickhofen
F. Grünwald
B. O. Maier
J. Diebold
S. Hauptmann
F. Kommoss
G. Emons
B. Radeleff
M. Gebhardt
N. Arnold
G. Calaminus
I. Weisse
J. Weis
J. Sehouli
D. Fink
A. Burges
A. Hasenburg
C. Eggert
Further Information

Publication History

Publication Date:
11 October 2013 (online)

1 Information about this Short Version

1.1 Editors

German Guideline Programme in Oncology (OL) of the Association of the Scientific Medical Societies in Germany (AWMF), the German Cancer Society (DKG) and German Cancer Aid (DKH).


1.2 Leading professional society

Germany Society for Gynaecology and Obstetrics (DGGG).

Zoom Image


1.3 Funding

This guideline was funded by German Cancer Aid as part of the German Guideline Programme in Oncology.


1.4 Contact

Office of the German Guideline Programme in Oncology

c/o Deutsche Krebsgesellschaft e. V.

Kuno-Fischer-Straße 8

14 057 Berlin, Germany


1.5 Citation

The German Guideline Programme in Oncology (German Cancer Society, German Cancer Aid, AWMF): S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumors, short version 1.0 (2013), AWMF registration number: 032–035OL,


1.6 Note

Medicine is continually subject to a process of development and change so that all information, particularly all information on diagnostic and therapeutic treatments, can only reproduce the state of knowledge at the time of printing of this guideline on care. The greatest possible care was taken when compiling these recommendations on therapy and the choice and dosage of medications. Users are requested to consult the package leaflets and check the summary of product characteristics provided by manufacturers and, when in doubt, to consult a specialist. In the interests of all concerned, please contact the OL editorial office if you find discrepancies or controversial issues. Users are responsible for all diagnostic and therapeutic applications, medications and dosages.

Registered trademarks (brand names) mentioned in this guideline have not been specifically labelled. When a specific indication lacks a trade name it should not be concluded that the brand name has not been registered. This guideline and all of its constituent parts is protected under copyright law. Any utilisation contrary to the provisions of copyright law without the written permission of the OL editorial office is prohibited and liable to prosecution. No part of this guideline may be reproduced in any form without the written permission of the OL editorial office. This applies in particular to copies, translations, microfilms and all storage, utilization and processing in electronic systems, intranets and the internet.


1.7 Additional guideline documents

The contents of this short version refer to the long version of the S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours available in German on the following websites

In addition to the short version, a number of other, supplementary documents are also available:

  • Guideline report on the compilation of the guideline

  • Long version

  • Patient guideline

All of these documents will also be available on the websites listed above.


1.8 Responsibilities

1.8.1 Authors of the guideline

Editorial team

  • Prof. Dr. Uwe Wagner (Co-ordinator, DGGG), Uni-Frauenklinik, Baldingerstraße, 35 043 Marburg, Germany

  • Dr. Philipp Harter (DGGG), Kliniken Essen-Mitte, Henricistraße 92, 45 136 Essen, Germany

  • PD Dr. Felix Hilpert (DGGG), Universitätsklinikum Schleswig Holstein, Campus Kiel, Klinik für Gynäkologie und Geburtshilfe, Arnold-Heller-Straße 3, Haus 24, 24 105 Kiel, Germany

  • PD Dr. Sven Mahner (DGGG), Universitätsklinikum Hamburg-Eppendorf, Klinik für Gynäkologie, Martinistraße 52, 20 246 Hamburg, Germany

  • Alexander Reuß, Koordinierungszentrum für Klinische Studien, Philipps-Universität Marburg, Karl-von Frisch-Straße 4, 35 043 Marburg, Germany

Participating scientific societies and authors

  • Prof. Dr. Andreas du Bois – Arbeitsgemeinschaft Gynäkologische Onkologie e. V. (AGO) [Gynaecological Oncology Working Group]

  • Prof. Dr. Edgar Petru – Arbeitsgemeinschaft für Gynäkologische Onkologie Austria (AGO AT) [Gynaecological Oncology Working Group Austria]

  • Prof. Dr. Werner Meier – AGO Study Group

  • Dr. Petra Ortner – Arbeitsgemeinschaft Supportive Maßnahmen in der Onkologie, Rehabilitation und Sozialmedizin (ASORS) [Working Group for Supportive Measures in Oncology, Rehabilitation and Epidemiology]

  • Dr. Klaus König – Berufsverband der Frauenärzte e. V. (BVF) [Professional Organisation of German Gynaecologists]

  • PD Dr. Katja Lindel – Deutsche Gesellschaft für Radioonkologie (DEGRO) [German Society for Radio-oncology]

  • Prof. Dr. Dieter Grab – Deutsche Gesellschaft für Ultraschall in der Medizin e. V. (DEGUM) [German Society for Ultrasound in Medicine]

  • Prof. Dr. Pompiliu Piso – Deutsche Gesellschaft für Allgemein- u. Viszeralchirurgie (DGAV) [German Society for General and Abdominal Surgery]

  • Prof. Dr. Olaf Ortmann – Deutsche Gesellschaft für Endokrinologie (DGE) [German Society for Endocrinology]

  • Prof. Dr. Ingo Runnebaum – Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) [Germany Society for Gynaecology and Obstetrics]

  • Prof. Dr. Jacobus Pfisterer – Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) [Germany Society for Gynaecology and Obstetrics]

  • PD Dr. Diana Lüftner – Deutsche Gesellschaft f. Hämatologie und Onkologie e. V. (DGHO) [German Society for Haematology and Oncology]

  • Prof. Dr. Norbert Frickhofen – Deutsche Gesellschaft für Innere Medizin e. V. (DEGIM) [German Society for Internal Medicine]

  • Prof. Dr. Frank Grünwald – Deutsche Gesellschaft für Nuklearmedizin e. V. (DGN) [German Society for Nuclear Medicine]

  • Dr. Bernd Oliver Maier – Deutsche Gesellschaft für Palliativmedizin e. V. (DGP) [German Society for Palliative Medicine]

  • Prof. Dr. Joachim Diebold, Prof. Dr. Steffen Hauptmann, Prof. Dr. Friedrich Kommoss – Deutsche Gesellschaft für Pathologie e. V. (DGP) [German Pathology Society]

  • Prof. Dr. Günter Emons – Deutsche Menopausengesellschaft e. V. (DMG) Deutsche Gesellschaft für Pathologie [German Pathology Society]

  • Dr. Boris Radeleff – Deutsche Röntgengesellschaft (DRG) [German Radiology Society]

  • Marion Gebhardt (patientsʼ representative) – Bundesverband der Frauenselbsthilfe nach Krebs e. V. [Federation of Womenʼs Self-help after Cancer Organisations]

  • Prof. Dr. Norbert Arnold – Deutsche Gesellschaft für Humangenetik (GfH) [German Society for Human Genetics]

  • Dr. Gabriele Calaminus – Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) [Society for Paediatric Oncology and Haematology]

  • Isolde Weisse – Konferenz Onkologischer Kranken- und Kinderkrankenpflege (KOK) [Conference for Oncologic Patient Care and Paediatric Patient Care]

  • Prof. Dr. Joachim Weis – Arbeitsgemeinschaft für Psychosoziale Onkologie (PSO) [Psycho-social Oncology Working Group]

  • Prof. Dr. Jalid Sehouli – Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO) [Northeast German Society for Gynaecological Oncology]

  • Prof. Dr. Daniel Fink – Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe (SGGG) [Swiss Society for Gynaecology and Obstetrics]

  • Dr. Alexander Burges – as an independent expert

  • Prof. Dr. Annette Hasenburg – as an independent expert

  • Dr. C. Eggert from the Medizinischen Dienst der Krankenversicherung in Hessen (MDK Hessen) [Medical Service of the Health Insurance Companies in Hesse] contributed to the discussions at the Consensus Conferences as an expert without voting rights.

Methodological Support

  1. The German Guideline Programme on Oncology

    • Prof. Dr. Ina Kopp, Marburg (AWMF)

    • Dr. Markus Follmann MPH MSc, Berlin (DKG) [German Cancer Society]

    • Dipl.-Soz.Wiss Thomas Langer (DKG) [German Cancer Society]

  2. External agencies:

  3. Coordination Centre for Clinical Studies of Philipps University Marburg, A. Reuß, Dr. D. Lubbe

  4. Bremen Institute for Prevention Research and Epidemiology (BIPS), Dr. K. Giersiepen

  5. The leading professional society:

  6. Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) [German Society for Gynaecology and Obstetrics], Prof. Dr. R. Kreienberg